Deals channel feed

Al­loy and Pyx­is spin out new 'com­pa­ny' around high-risk I/O, im­munol­o­gy tar­gets

4 years ago
Startups

Pieris inks res­pi­ra­to­ry part­ner­ship with Genen­tech, adding an­oth­er to slate of mile­stone-heavy deals

4 years ago

The $70B ques­tion: What’s Pfiz­er go­ing to do with all that Covid vac­cine cash?

4 years ago
Bioregnum

A CRO look­ing to build its man­u­fac­tur­ing side busi­ness has a new par­ent af­ter Keen­sight snaps up ma­jor­i­ty stake

4 years ago
Outsourcing
Manufacturing

Rare dis­ease play­er that went pub­lic in biotech's go-go years merges with spe­cial­ty phar­ma in all-stock deal — at a frac­tion of the de­but price

4 years ago

A ge­net­ics test­ing out­fit is bail­ing on its CRO ser­vices, choos­ing in­stead to re­fo­cus around pre­ci­sion drugs

4 years ago
Outsourcing

Arie Bellde­grun's vi­sion for Gink­go comes in­to view, as the now $15B com­pa­ny teams with Bio­gen on gene ther­a­py

4 years ago

Bris­tol My­ers ex­pands Cel­gene-era deal with Ex­sci­en­tia, tak­ing its AI R&D en­gine to the next step

4 years ago
AI

Bris­tol My­ers bets big on an­ti-TIG­IT bis­pe­cif­ic from Agenus in a part­ner­ship worth $1.5B+

4 years ago

Charles Riv­er keeps adding on to its CD­MO arm, snatch­ing up a vi­ral vec­tor play­er for a tidy $350M

4 years ago
Manufacturing

Per­cep­tive's Chi­na up­start Lian­Bio con­tin­ues swing­ing deals, team­ing up with lead Xon­toge­ny biotech Lan­dos in IBD

4 years ago
China

PerkinElmer hits the check­book again, this time dol­ing out $260M for next-gen ther­a­py bioser­vices firm

4 years ago
Manufacturing

Bio­gen push­es in a fresh stack of chips and starts prep­ping a glob­al R&D game plan af­ter watch­ing the cards turn on ear­ly throm­bolyt­ic da­ta

5 years ago
R&D

Bio­gen en­lists un­der-the-radar AAV en­gi­neers as it pumps gene ther­a­pies in­to the pipeline

5 years ago

Lil­ly en­lists a long-in­cu­bat­ing RNA up­start in new $1.25B part­ner­ship

5 years ago

Ab­b­Vie makes a hefty play to boost aes­thet­ics busi­ness, pay­ing $550M for non-in­va­sive body sculpt­ing de­vice

5 years ago
Pharma

With no up­front pay­ment or mile­stones on the line, Nkar­ta and CRISPR join forces on CAR-NK search

5 years ago
R&D

Al­ta­sciences, true to its word, ex­pands its foot­print with ac­qui­si­tion of Penn­syl­va­nia CRO

5 years ago
Manufacturing

Bounc­ing back from a shock­ing CRL, Athenex shares soar with buy­out of nat­ur­al killer T cell play­er

5 years ago

A biotech with a yen for pricey rare dis­ease drugs — and bar­gain base­ment shop­ping — adopts an­oth­er or­phan in lat­est M&A pact

5 years ago

Sig­ma-Aldrich hit with $9M fine for mis­lead­ing in­fo dur­ing Mer­ck KGaA merg­er

5 years ago
FDA+

Astel­las walks away from $450M+ Cy­to­ki­net­ics pact af­ter tak­ing a few ex­tra months to see progress

5 years ago

A mus­cled up Mod­er­na fi­nal­ly joins the CO­V­AX crew, pledg­ing 500M dos­es for low-in­come coun­tries

5 years ago
Coronavirus

Am­plyx laid out a promis­ing path to a piv­otal an­ti­fun­gal drug tri­al, and now Pfiz­er is scoop­ing it all up in a buy­out

5 years ago
First page Previous page 75767778798081 Next page Last page
A service from the Financial Times